Odevixibat-13C6

Odevixibat-13C6 is 13C labeled Odevixibat (HY-109120) . Odevixibat (A4250) is a selective and orally active ileal apical sodium-dependent bile acid transporter (ASBT) inhibitor. Odevixibat decreases cholestatic liver and bile duct injury in mice model. Odevixibat has the potential for the treatment of primary biliary cirrhosis[1].

Product Specifications

Product Name Alternative

A4250-13C6

UNSPSC

12352005

Target

Apical Sodium-Dependent Bile Acid Transporter; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/odevixibat-13c6.html

Solubility

10 mM in DMSO

Smiles

CCCCC(CCCC)(NS(=O)(C1=CC(OCC(N[C@H](C2=CC=C(C=C2)O)C(N[C@H](C(O)=O)CC)=O)=O)=C(C=C13)SC)=O)CN3[13C]4=[13CH][13CH]=[13CH][13CH]=[13CH]4

Molecular Formula

C31 13C6H48N4O8S2

Molecular Weight

746.88

References & Citations

[1]Baghdasaryan A, et al. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.J Hepatol. 2016 Mar;64 (3) :674-81.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.